Management of Vascular Endothelial Growth Factor and Multikinase Inhibitor Side Effects

Laura S. Wood

vascular endothelial growth factor receptor
CJON 2009, 13(6), 13-18. DOI: 10.1188/09.CJON.S2.13-18

The availability of vascular endothelial growth factor and multikinase inhibitors (MKIs) has enhanced treatment strategies for patients with advanced kidney cancer. Side effects associated with the agents include dermatologic toxicities, gastrointestinal toxicities, and hematologic and metabolic abnormalities that may interfere with treatment adherence. Nurses play a key role in managing side effects associated with emerging therapies. This article presents a case study to illustrate side-effect management strategies for patients receiving MKIs for the treatment of advanced renal cell carcinoma.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.